Preclinical models
Which cell lines, PDX, mouse models and organoid banks exist for 32 cancers and 19 targets: 222 cell lines with Cellosaurus accessions (174 in DepMap, so their dependencies and drug sensitivities are one click away), the mouse models with the paper that made them, and where to request patient-derived models.
495 models
| Identifiers | Genotype | Why it is used / alleles | Source | ||
|---|---|---|---|---|---|
| CVCL_2270, ACH-001001 | Osteosarcoma | KRAS | Highly metastatic KRAS-transformed derivative of HOS. | none | |
| CVCL_1045, ACH-000956 | Prostate cancer, Androgen receptor, PSMA | Androgen receptor, PSMA | Expresses AR-V7 splice variant; enzalutamide-resistant; moderate PSMA. | none | |
4-NQO carcinogen model 4-nitroquinoline 1-oxide in drinking water Oral dysplasia to SCC over months with tobacco-like mutations. | none | Head and neck squamous cell carcinoma | none | Oral dysplasia to SCC over months with tobacco-like mutations. | Mouse Tumor Biology database (JAX) |
4T1 Malignant neoplasms of the mouse mammary gland Mouse (BALB/c) syngeneic TNBC-like line; spontaneous lung metastasis; the standard immunotherapy model for breast. | CVCL_0125 | Triple-negative breast cancer, PD-1 | PD-1 | Mouse (BALB/c) syngeneic TNBC-like line; spontaneous lung metastasis; the standard immunotherapy model for breast. | none |
| CVCL_0126, ACH-000905 | Bladder & urothelial cancer | Nectin-4 | Basal/squamous-like, Nectin-4 high; enfortumab vedotin model. | none | |
| CVCL_VI66 | Multiple myeloma | none | Mouse (KaLwRij) myeloma; the syngeneic bone-disease model. | none | |
| CVCL_1051, ACH-000649 | Renal cell carcinoma | HIF-2α | VHL-null, HIF-2alpha dependent clear-cell line; the belzutifan model. | none | |
| CVCL_1054, ACH-001307 | Thyroid cancer, BRAF | BRAF, TP53 | Anaplastic carcinoma, BRAF V600E, TP53 R248G. | none | |
| CVCL_0132, ACH-000219 | Melanoma, BRAF | BRAF | BRAF V600E; the standard vemurafenib and dabrafenib line. | none | |
A-431 Skin squamous cell carcinoma Vulval squamous line with massive EGFR amplification; the antibody and ADC binding standard. | CVCL_0037, ACH-001328 | EGFR | EGFR | Vulval squamous line with massive EGFR amplification; the antibody and ADC binding standard. | none |
| CVCL_1056, ACH-000555 | Renal cell carcinoma | HIF-2α | VHL-null, HIF-2alpha expressing. | none | |
| CVCL_0080, ACH-000052 | Ewing sarcoma | EWSR1-FLI1 fusion, BRAF | EWSR1::FLI1 type 1, BRAF V600E (unusual), CDKN2A-null. | none | |
A549 Lung adenocarcinoma KRAS G12S, STK11-null adenocarcinoma; the default lung line for everything and therefore representative of little. | CVCL_0023, ACH-000681 | Non-small-cell lung cancer, KRAS | KRAS | KRAS G12S, STK11-null adenocarcinoma; the default lung line for everything and therefore representative of little. | none |
AB1 and AE17 Mouse asbestos-induced syngeneic lines (BALB/c and C57BL/6). | not resolved | Mesothelioma | PD-1 | Mouse asbestos-induced syngeneic lines (BALB/c and C57BL/6). | none |
| CVCL_0139, ACH-000880 | Gastric & gastro-oesophageal junction cancer | KRAS, PIK3CA / PI3K-alpha | KRAS G12D, PIK3CA E453K, CDH1-mutant; diffuse-like. | none | |
| CVCL_0028, ACH-000940 | Endometrial cancer | FGFR2 | FGFR2 N550K, PTEN-null; the FGFR2 endometrial line. | none | |
Apc Min Apc Min/+ (germline truncation) Dozens of small-intestinal adenomas; few progress to carcinoma and few are colonic. | none | Colorectal cancer | none | Dozens of small-intestinal adenomas; few progress to carcinoma and few are colonic. | Moser et al., Science 1990 |
| CVCL_IV72 | Endometrial cancer | HER2, TP53 | Uterine serous carcinoma, HER2-amplified. | none | |
Asbestos-exposed Nf2 / Cdkn2a Intraperitoneal asbestos in Nf2+/- and Cdkn2a-deficient mice Accelerated mesothelioma with human-like genetics. | none | Mesothelioma | none | Accelerated mesothelioma with human-like genetics. | Jongsma et al., Cancer Cell 2008 |
| CVCL_0152, ACH-000222 | Pancreatic ductal adenocarcinoma, KRAS | KRAS, TROP2 | KRAS G12D, ascites-derived; TROP2- and CLDN18.2-expressing. | none | |
B16-F10 Mouse melanoma Mouse (C57BL/6) poorly immunogenic melanoma; the classic checkpoint-resistant syngeneic model. | CVCL_0159 | Melanoma, PD-1 | PD-1, CTLA-4 | Mouse (C57BL/6) poorly immunogenic melanoma; the classic checkpoint-resistant syngeneic model. | none |
Ba/F3 Mouse pro-B line made IL-3 independent by any kinase driver; the universal engine for kinase and resistance mutation panels. | CVCL_0161 | Acute myeloid leukaemia | FLT3, BCR::ABL1, ALK, EGFR, KIT | Mouse pro-B line made IL-3 independent by any kinase driver; the universal engine for kinase and resistance mutation panels. | none |
Ba/F3 BCR-ABL1 mutants T315I, E255K, Y253H and myristoyl-pocket panels. | not resolved | BCR::ABL1 | BCR::ABL1 | T315I, E255K, Y253H and myristoyl-pocket panels. | none |
Ba/F3 EGFR panels Engineered exon 20 insertion, C797S and other alleles in the IL-3-dependent Ba/F3 background. | not resolved | EGFR | EGFR | Engineered exon 20 insertion, C797S and other alleles in the IL-3-dependent Ba/F3 background. | none |
Ba/F3 EML4-ALK mutants G1202R, L1196M, compound mutations; the lorlatinib and neladalkib profiling panel. | not resolved | ALK | ALK | G1202R, L1196M, compound mutations; the lorlatinib and neladalkib profiling panel. | none |
Ba/F3 ERBB2 exon 20 Engineered YVMA insertion lines for zongertinib- and sevabertinib-type TKIs. | not resolved | HER2 | HER2 | Engineered YVMA insertion lines for zongertinib- and sevabertinib-type TKIs. | none |
Ba/F3 FLT3-ITD and D835Y Engineered alleles including F691L gatekeeper. | not resolved | FLT3 | FLT3 | Engineered alleles including F691L gatekeeper. | none |
BBN carcinogen model N-butyl-N-(4-hydroxybutyl)nitrosamine in drinking water Muscle-invasive, basal-like tumours with a human-like mutational spectrum after about 20 weeks. | none | Bladder & urothelial cancer | none | Muscle-invasive, basal-like tumours with a human-like mutational spectrum after about 20 weeks. | Mouse Tumor Biology database (JAX) |
| CVCL_0153, ACH-000456 | Thyroid cancer | BRAF, TP53 | Papillary carcinoma, BRAF V600E, TP53-mutant. | none | |
Braf CA (V600E) conditional Cre-activated Braf V600E used in melanoma, lung, thyroid and colon models The shared conditional allele. | none | BRAF | none | The shared conditional allele. | Dankort et al., Nat Genet 2009 |
Braf V600E / Pten Tyr-CreERT2; Braf CA; Pten flox Tamoxifen-inducible melanoma with metastasis; the reference model for BRAF/MEK inhibition and immunotherapy combinations. | none | Melanoma | none | Tamoxifen-inducible melanoma with metastasis; the reference model for BRAF/MEK inhibition and immunotherapy combinations. | Dankort et al., Nat Genet 2009 |
Brain Tumor Resource Lab (Olson) Fred Hutch collection of paediatric brain tumour PDX lines shared free of charge. | none | Medulloblastoma | none | Fred Hutch collection of paediatric brain tumour PDX lines shared free of charge. | portal |
Brca1 / Trp53 conditional K14-Cre; Brca1 flox; Trp53 flox Basal-like tumours mirroring BRCA1 carriers; PARP-inhibitor resistance models derive from it. | none | Triple-negative breast cancer | none | Basal-like tumours mirroring BRCA1 carriers; PARP-inhibitor resistance models derive from it. | Liu et al., PNAS 2007 |
BT-474 Invasive breast carcinoma of no special type HER2-amplified, ER-positive, PIK3CA K111N; the T-DM1 and T-DXd xenograft standard. | CVCL_0179, ACH-000927 | HER2-positive breast cancer, HER2 | HER2 | HER2-amplified, ER-positive, PIK3CA K111N; the T-DM1 and T-DXd xenograft standard. | none |
BT142 Oligoastrocytoma Glioma, IDH1 R132H (hemizygous); one of few IDH-mutant glioma lines that grows. | CVCL_D718 | IDH1 / IDH2 | IDH1 / IDH2 | Glioma, IDH1 R132H (hemizygous); one of few IDH-mutant glioma lines that grows. | none |
BxPC-3 Pancreatic ductal adenocarcinoma KRAS wild-type, TP53 Y220C; the control line for KRAS studies and the Y220C reactivator line. | CVCL_0186, ACH-000535 | Pancreatic ductal adenocarcinoma, TP53, TROP2 | TP53, TROP2 | KRAS wild-type, TP53 Y220C; the control line for KRAS studies and the Y220C reactivator line. | none |
C-33 A Human papillomavirus-independent cervical squamous cell carcinoma HPV-negative cervical carcinoma with RB1 and TP53 mutations. | CVCL_1094, ACH-001333 | Cervical cancer | TP53 | HPV-negative cervical carcinoma with RB1 and TP53 mutations. | none |
| none | Triple-negative breast cancer | none | Basal-like mammary carcinoma. | Mouse Tumor Biology database (JAX) | |
| CVCL_4782 | PSMA | PSMA | PSMA-high, castration-resistant. | none | |
| CVCL_4784 | Androgen receptor | Androgen receptor | Castration-resistant LNCaP derivative, bone-metastatic. | none | |
| CVCL_0234, ACH-000433 | Renal cell carcinoma | none | VHL wild-type clear-cell line (metastasis-derived). | none | |
| CVCL_1107, ACH-000832 | Head and neck squamous cell carcinoma | EGFR, TP53 | Tongue SCC, HPV-negative, TP53 H193L. | none | |
| CVCL_0608, ACH-000511 | KRAS | KRAS | Lung, G12C. | none | |
| CVCL_0609, ACH-000392 | Non-small-cell lung cancer, TROP2 | HER2, TROP2 | HER2-amplified adenocarcinoma. | none | |
| CVCL_1115, ACH-000783 | HR-positive / HER2-negative breast cancer, Estrogen receptor | Estrogen receptor | ER-positive with CDH1 loss (lobular-like). | none | |
| CVCL_0237, ACH-000354 | Pancreatic ductal adenocarcinoma, KRAS, BRCA1 / BRCA2 | KRAS, BRCA1 / BRCA2, PARP | KRAS G12V, BRCA2 6174delT; PARP-inhibitor model. | none | |
CaSki Human papillomavirus-related cervical squamous cell carcinoma HPV16 (and HPV18 sequences) squamous line. | CVCL_1100, ACH-001336 | Cervical cancer | none | HPV16 (and HPV18 sequences) squamous line. | none |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Non-small-cell lung cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Small-cell lung cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | HR-positive / HER2-negative breast cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | HER2-positive breast cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Triple-negative breast cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Colorectal cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Pancreatic ductal adenocarcinoma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Prostate cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Melanoma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Glioma & glioblastoma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Ovarian cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Gastric & gastro-oesophageal junction cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Hepatocellular carcinoma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Bladder & urothelial cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Renal cell carcinoma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Head and neck squamous cell carcinoma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Mesothelioma | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Biliary tract cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Gastrointestinal stromal tumour | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Endometrial cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Cervical cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Oesophageal cancer | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | KRAS | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | EGFR | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | HER2 | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | BRAF | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | Estrogen receptor | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | BRCA1 / BRCA2 | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | KIT | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Champions Oncology Commercial bank of over 1,500 characterised PDX models (Lumin platform). | none | TROP2 | none | Commercial bank of over 1,500 characterised PDX models (Lumin platform). | portal |
Childhood Solid Tumour Network (St. Jude) Free paediatric solid-tumour orthotopic PDX models with genomics. | none | Neuroblastoma | none | Free paediatric solid-tumour orthotopic PDX models with genomics. | portal |
Childhood Solid Tumour Network (St. Jude) Free paediatric solid-tumour orthotopic PDX models with genomics. | none | Ewing sarcoma | none | Free paediatric solid-tumour orthotopic PDX models with genomics. | portal |
Childhood Solid Tumour Network (St. Jude) Free paediatric solid-tumour orthotopic PDX models with genomics. | none | Osteosarcoma | none | Free paediatric solid-tumour orthotopic PDX models with genomics. | portal |
Childhood Solid Tumour Network (St. Jude) Free paediatric solid-tumour orthotopic PDX models with genomics. | none | Medulloblastoma | none | Free paediatric solid-tumour orthotopic PDX models with genomics. | portal |
| CVCL_0218, ACH-001039 | BRAF | BRAF | Colorectal, V600E. | none | |
| CVCL_2420, ACH-000278 | Ovarian cancer, BRCA1 / BRCA2 | BRCA1 / BRCA2, PARP | BRCA1-mutant high-grade serous line. | none | |
| CVCL_ZJ44 | Glioma & glioblastoma | PD-1 | Mouse syngeneic glioma with stem-like features; less immunogenic than GL261. | none | |
CT26 Mouse colon adenocarcinoma Mouse (BALB/c) KRAS G12D colon line; MSS-like, moderately immunogenic. | CVCL_7254 | Colorectal cancer, KRAS, PD-1 | PD-1, KRAS | Mouse (BALB/c) KRAS G12D colon line; MSS-like, moderately immunogenic. | none |
| CVCL_1155, ACH-000055 | Medulloblastoma | none | Group 3/4-like, MYC-expressing. | none | |
D425 Med Medulloblastoma, non-WNT/non-SHH, group 3 Group 3, MYC-amplified; aggressive orthotopic model. | CVCL_1275, ACH-001053 | Medulloblastoma | none | Group 3, MYC-amplified; aggressive orthotopic model. | none |
Daoy Medulloblastoma, SHH-activated, TP53-mutant SHH-like, TP53-mutant; the most used medulloblastoma line but not group-representative. | CVCL_1167, ACH-000211 | Medulloblastoma | Smoothened, TP53 | SHH-like, TP53-mutant; the most used medulloblastoma line but not group-representative. | none |
Daudi EBV-related Burkitt lymphoma Burkitt; beta-2-microglobulin null (no HLA class I), useful for MHC-independent killing. | CVCL_0008, ACH-000786 | CD19 | CD19, CD20 | Burkitt; beta-2-microglobulin null (no HLA class I), useful for MHC-independent killing. | none |
| CVCL_1171, ACH-000207 | Head and neck squamous cell carcinoma | EGFR | Pharyngeal SCC, HPV-negative. | none | |
| CVCL_0248, ACH-001061 | Colorectal cancer | KRAS | KRAS G13D, MSI-high; used for PARP and mismatch-repair work. | none | |
| CVCL_HD56 | BRCA1 / BRCA2 | BRCA1 / BRCA2, PARP | Isogenic colorectal knock-out pair (Horizon). | none | |
DMS 114 Thoracic SMARCA4-deficient undifferentiated tumor Adherent SCLC line; SLFN11-expressing, used for TOP1 and PARP sensitivity. | CVCL_1174, ACH-000530 | Small-cell lung cancer | none | Adherent SCLC line; SLFN11-expressing, used for TOP1 and PARP sensitivity. | none |
| CVCL_0105, ACH-000979 | Prostate cancer, PSMA | PSMA | AR-negative, brain-metastasis derived. | none | |
EGFR L858R / T790M (tet-inducible) CCSP-rtTA; TetO-EGFR L858R or L858R+T790M Doxycycline-inducible mutant EGFR; tumours regress when the transgene is switched off. | none | Non-small-cell lung cancer | none | Doxycycline-inducible mutant EGFR; tumours regress when the transgene is switched off. | Politi et al., Genes Dev 2006 |
| none | EGFR | none | Inducible mutant EGFR lung tumours. | Politi et al., Genes Dev 2006 | |
| CVCL_1193, ACH-001494 | Biliary tract cancer | KRAS | Extrahepatic, KRAS G12D. | none | |
Eml4-Alk (CRISPR) In vivo Cas9-induced Eml4-Alk inversion Endogenous fusion, crizotinib-sensitive tumours. | none | Non-small-cell lung cancer | none | Endogenous fusion, crizotinib-sensitive tumours. | Maddalo et al., Nature 2014 |
| none | ALK | none | Endogenous fusion lung tumours. | Maddalo et al., Nature 2014 | |
| CVCL_1923 | PD-1 | PD-1 | Mouse breast; responsive. | none | |
EurOPDX European PDX consortium; models discoverable through the PDCM Finder. | none | Non-small-cell lung cancer | none | European PDX consortium; models discoverable through the PDCM Finder. | portal |
EurOPDX European PDX consortium; models discoverable through the PDCM Finder. | none | Small-cell lung cancer | none | European PDX consortium; models discoverable through the PDCM Finder. | portal |
EurOPDX European PDX consortium; models discoverable through the PDCM Finder. | none | HR-positive / HER2-negative breast cancer | none | European PDX consortium; models discoverable through the PDCM Finder. | portal |
EurOPDX European PDX consortium; models discoverable through the PDCM Finder. | none | Triple-negative breast cancer | none | European PDX consortium; models discoverable through the PDCM Finder. | portal |
EurOPDX European PDX consortium; models discoverable through the PDCM Finder. | none | Colorectal cancer | none | European PDX consortium; models discoverable through the PDCM Finder. | portal |
EurOPDX European PDX consortium; models discoverable through the PDCM Finder. | none | Pancreatic ductal adenocarcinoma | none | European PDX consortium; models discoverable through the PDCM Finder. | portal |
EurOPDX European PDX consortium; models discoverable through the PDCM Finder. | none | Prostate cancer | none | European PDX consortium; models discoverable through the PDCM Finder. | portal |
EurOPDX European PDX consortium; models discoverable through the PDCM Finder. | none | Melanoma | none | European PDX consortium; models discoverable through the PDCM Finder. | portal |
EurOPDX European PDX consortium; models discoverable through the PDCM Finder. | none | Ovarian cancer | none | European PDX consortium; models discoverable through the PDCM Finder. | portal |
EurOPDX European PDX consortium; models discoverable through the PDCM Finder. | none | Gastric & gastro-oesophageal junction cancer | none | European PDX consortium; models discoverable through the PDCM Finder. | portal |
| CVCL_1658, ACH-000499 | Ewing sarcoma | EWSR1-FLI1 fusion | EWSR1::FLI1, used for IGF1R and PARP work. | none | |
Eμ-Myc Myc under the immunoglobulin heavy-chain enhancer Pre-B and B-cell lymphoma; the classic apoptosis and BCL2-family model. | none | Diffuse large B-cell lymphoma | none | Pre-B and B-cell lymphoma; the classic apoptosis and BCL2-family model. | Adams et al., Nature 1985 |
| none | CD19 | none | Syngeneic B-cell lymphoma for murine CD19 CAR-T studies. | Adams et al., Nature 1985 | |
Eμ-TCL1 Human TCL1 under the immunoglobulin heavy-chain enhancer CD5-positive B-cell leukaemia at about 12 months; transplantable; the model used for ibrutinib and venetoclax preclinical work. | none | Chronic lymphocytic leukaemia | none | CD5-positive B-cell leukaemia at about 12 months; transplantable; the model used for ibrutinib and venetoclax preclinical work. | Bichi et al., PNAS 2002 |
| none | BTK | none | CLL model used for BTK-inhibitor pharmacology. | Bichi et al., PNAS 2002 | |
| CVCL_1218, ACH-000846 | Head and neck squamous cell carcinoma | EGFR, TP53 | Hypopharyngeal SCC, HPV-negative, TP53 R248L; EGFR-high. | none | |
Fallopian-tube Trp53 / Brca1 / Pten Pax8-rtTA; TetO-Cre; Trp53; Brca1; Pten Serous tubal intraepithelial carcinoma progressing to HGSOC, supporting the fallopian-tube origin. | none | Ovarian cancer | none | Serous tubal intraepithelial carcinoma progressing to HGSOC, supporting the fallopian-tube origin. | Perets et al., Cancer Cell 2013 |
| CVCL_2045, ACH-001500 | Oesophageal cancer | TP53 | Oesophageal adenocarcinoma, TP53-mutant, HER2-negative. | none | |
Flt3-ITD knock-in Flt3 ITD at the endogenous locus Myeloproliferative disease; co-operates with Npm1c or Dnmt3a loss to give AML. | none | Acute myeloid leukaemia | none | Myeloproliferative disease; co-operates with Npm1c or Dnmt3a loss to give AML. | Lee et al., Cancer Cell 2007 |
| none | FLT3 | none | Myeloproliferative disease; AML with a second hit. | Lee et al., Cancer Cell 2007 | |
GIST-T1 Gastrointestinal stromal tumor KIT exon 11 deletion; imatinib-sensitive; the parent of several resistant derivatives. | CVCL_4976, ACH-002332 | Gastrointestinal stromal tumour, KIT | KIT | KIT exon 11 deletion; imatinib-sensitive; the parent of several resistant derivatives. | none |
| CVCL_7040 | Gastrointestinal stromal tumour, KIT | KIT | KIT exon 11 plus V654A secondary mutation; imatinib-resistant. | none | |
| CVCL_7041 | Gastrointestinal stromal tumour, KIT | KIT | KIT exon 11 plus D820A secondary mutation; imatinib-resistant. | none | |
| CVCL_7044 | Gastrointestinal stromal tumour, KIT | KIT | KIT K642E (exon 13), imatinib-sensitive. | none | |
GL261 Mouse glioblastoma Mouse (C57BL/6) syngeneic glioma; immunogenic, so it overstates immunotherapy effects. | CVCL_Y003 | Glioma & glioblastoma | PD-1 | Mouse (C57BL/6) syngeneic glioma; immunogenic, so it overstates immunotherapy effects. | none |
| CVCL_4213 | Diffuse large B-cell lymphoma, BTK | BTK, CD79b | ABC, CD79B and MYD88 mutant. | none | |
HCC1806 Breast acantholytic squamous cell carcinoma Basal-like, TROP2-high; used for sacituzumab govitecan. | CVCL_1258, ACH-000624 | Triple-negative breast cancer, TROP2 | TROP2 | Basal-like, TROP2-high; used for sacituzumab govitecan. | none |
| CVCL_0290, ACH-000223 | Triple-negative breast cancer, BRCA1 / BRCA2 | BRCA1 / BRCA2, PARP | BRCA1 5382insC germline line. | none | |
| CVCL_1259, ACH-000859 | HER2-positive breast cancer, HER2 | HER2, PIK3CA / PI3K-alpha | HER2-amplified, PIK3CA H1047R; intrinsically trastuzumab-resistant. | none | |
| CVCL_1269, ACH-000066 | EGFR | EGFR | Exon 19 deletion; EMT-type resistance models. | none | |
HCC827 Lung adenocarcinoma EGFR exon 19 deletion with amplification; MET-amplified resistant derivatives exist. | CVCL_2063, ACH-000012 | Non-small-cell lung cancer, EGFR | EGFR, MET | EGFR exon 19 deletion with amplification; MET-amplified resistant derivatives exist. | none |
HCT 116 Colon carcinoma KRAS G13D, PIK3CA H1047R, MSI-high; the most used CRC line and the basis of many isogenic knock-out pairs (TP53, KRAS). | CVCL_0291, ACH-000971 | Colorectal cancer, KRAS, TP53 | KRAS, PIK3CA / PI3K-alpha, TP53 | KRAS G13D, PIK3CA H1047R, MSI-high; the most used CRC line and the basis of many isogenic knock-out pairs (TP53, KRAS). | none |
| CVCL_0293, ACH-000954 | Endometrial cancer | KRAS, PIK3CA / PI3K-alpha | Endometrioid, KRAS G12D, PIK3CA G1049R; MSI-high. | none | |
HeLa Human papillomavirus-related endocervical adenocarcinoma HPV18 adenocarcinoma; the first human cell line and the most contaminating one. | CVCL_0030, ACH-001086 | Cervical cancer | none | HPV18 adenocarcinoma; the first human cell line and the most contaminating one. | none |
| CVCL_0326, ACH-000625 | Hepatocellular carcinoma | TP53 | HBV-integrated, TP53-null HCC. | none | |
Hep-G2 Hepatoblastoma Hepatoblastoma-derived (not HCC) despite universal use; NRAS Q61L, wild-type TP53. | CVCL_0027, ACH-000739 | Hepatocellular carcinoma | none | Hepatoblastoma-derived (not HCC) despite universal use; NRAS Q61L, wild-type TP53. | none |
Hepa 1-6 Hepatocellular carcinoma of the mouse Mouse (C57L) syngeneic hepatoma; orthotopic immunotherapy model. | CVCL_0327 | Hepatocellular carcinoma | PD-1 | Mouse (C57L) syngeneic hepatoma; orthotopic immunotherapy model. | none |
HepG2-GPC3 and JHH-7 GPC3-high models used for GPC3 CAR-T and bispecifics. | not resolved | Hepatocellular carcinoma | Glypican-3 | GPC3-high models used for GPC3 CAR-T and bispecifics. | none |
| CVCL_Y547, ACH-001520 | Chronic lymphocytic leukaemia | none | EBV-transformed CLL line with unmutated IGHV. | none | |
HL-60 Adult acute myeloid leukemia with maturation NRAS Q61L, CDKN2A-deleted promyelocytic line; TP53-null. | CVCL_0002, ACH-000002 | Acute myeloid leukaemia | none | NRAS Q61L, CDKN2A-deleted promyelocytic line; TP53-null. | none |
| CVCL_0003 | KIT | KIT | Mast-cell leukaemia, D816V (HMC-1.2) and V560G; the mastocytosis line. | none | |
| CVCL_0313, ACH-000094 | Pancreatic ductal adenocarcinoma, KRAS | KRAS | KRAS G12D, well differentiated, classical subtype. | none | |
| CVCL_0317, ACH-000054 | IDH1 / IDH2 | IDH1 / IDH2 | Fibrosarcoma, IDH1 R132C; the most used endogenous mutant-IDH1 line. | none | |
| CVCL_0320, ACH-000552 | Colorectal cancer, BRAF | BRAF, TP53 | BRAF V600E, TP53 R273H, MSS. | none | |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Non-small-cell lung cancer | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | HR-positive / HER2-negative breast cancer | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | HER2-positive breast cancer | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Triple-negative breast cancer | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Colorectal cancer | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Pancreatic ductal adenocarcinoma | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Ovarian cancer | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Gastric & gastro-oesophageal junction cancer | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Hepatocellular carcinoma | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Bladder & urothelial cancer | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Head and neck squamous cell carcinoma | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Biliary tract cancer | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Endometrial cancer | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Cervical cancer | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Oesophageal cancer | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | KRAS | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | HER2 | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | BRAF | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | Estrogen receptor | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
HUB Organoids Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | none | BRCA1 / BRCA2 | none | Hubrecht-founded biobank of patient-derived organoids across tumour types; academic and commercial access. | portal |
| CVCL_0324, ACH-000976 | Biliary tract cancer | KRAS, TP53 | Intrahepatic, KRAS G12D, TP53-mutant. | none | |
| CVCL_0336, ACH-000480 | Hepatocellular carcinoma, TP53 | TP53 | TP53 Y220C HCC line; also the hepatitis C replicon host. | none | |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Non-small-cell lung cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Small-cell lung cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | HR-positive / HER2-negative breast cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | HER2-positive breast cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Triple-negative breast cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Colorectal cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Pancreatic ductal adenocarcinoma | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Prostate cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Melanoma | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Glioma & glioblastoma | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Ovarian cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Gastric & gastro-oesophageal junction cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Hepatocellular carcinoma | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Bladder & urothelial cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Renal cell carcinoma | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Head and neck squamous cell carcinoma | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Biliary tract cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Endometrial cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Oesophageal cancer | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | KRAS | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | EGFR | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | HER2 | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | BRAF | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | ALK | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Estrogen receptor | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | TP53 | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | BRCA1 / BRCA2 | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | IDH1 / IDH2 | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | Androgen receptor | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Human Cancer Models Initiative (HCMI) Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | none | TROP2 | none | Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing. | portal |
Humanised-mouse PDX (CD34+ or PBMC engrafted) Human immune system mice bearing PDX, the only patient-derived setting for human checkpoint antibodies. | none | PD-1 | none | Human immune system mice bearing PDX, the only patient-derived setting for human checkpoint antibodies. | portal |
Hydrodynamic transposon models Myc, Ctnnb1 or Akt transposons with or without sgTrp53 delivered by hydrodynamic tail-vein injection Weeks to tumours in immunocompetent mice; genotype chosen per experiment. | none | Hepatocellular carcinoma | none | Weeks to tumours in immunocompetent mice; genotype chosen per experiment. | Mouse Tumor Biology database (JAX) |
ICC13-7 and CCLP-1 FGFR2-fusion (ICC13-7) and FGFR2-dependent lines used for pemigatinib and futibatinib resistance studies. | not resolved | Biliary tract cancer | FGFR2 | FGFR2-fusion (ICC13-7) and FGFR2-dependent lines used for pemigatinib and futibatinib resistance studies. | none |
ID8 Mouse (C57BL/6) ovarian surface epithelial line; ID8 Trp53-/- Brca2-/- derivatives model HGSOC for immunotherapy. | CVCL_IU14 | Ovarian cancer | PD-1, BRCA1 / BRCA2 | Mouse (C57BL/6) ovarian surface epithelial line; ID8 Trp53-/- Brca2-/- derivatives model HGSOC for immunotherapy. | none |
ID8 syngeneic Spontaneously transformed C57BL/6 ovarian surface epithelium Intraperitoneal disease with ascites; the standard immunotherapy model. | none | Ovarian cancer | none | Intraperitoneal disease with ascites; the standard immunotherapy model. | Roby et al., Carcinogenesis 2000 |
Idh2 R172K; Kras G12D Albumin-Cre; Idh2 R172K; Kras LSL-G12D Mutant IDH blocks hepatocyte differentiation and co-operates with Kras to give intrahepatic cholangiocarcinoma. | none | Biliary tract cancer | none | Mutant IDH blocks hepatocyte differentiation and co-operates with Kras to give intrahepatic cholangiocarcinoma. | Saha et al., Nature 2014 |
| none | IDH1 / IDH2 | none | Intrahepatic cholangiocarcinoma. | Saha et al., Nature 2014 | |
| CVCL_0346, ACH-000310 | Neuroblastoma | GD2 | MYCN-amplified, ALK wild-type; GD2-high. | none | |
Ishikawa Type I endometrial adenocarcinoma Endometrioid, ER-positive, PTEN-null, PIK3R1-mutant; the endocrine and PI3K model. | CVCL_2529, ACH-000961 | Endometrial cancer, Estrogen receptor | Estrogen receptor, AKT | Endometrioid, ER-positive, PTEN-null, PIK3R1-mutant; the endocrine and PI3K model. | none |
| CVCL_1865, ACH-000357 | CD19 | CD19, CD20, BTK | Mantle-cell lymphoma. | none | |
JIMT-1 Breast ductal carcinoma HER2-amplified, trastuzumab-resistant from the outset (PIK3CA H1047R, low PTEN). | CVCL_2077, ACH-000711 | HER2-positive breast cancer | HER2 | HER2-amplified, trastuzumab-resistant from the outset (PIK3CA H1047R, low PTEN). | none |
Jurkat Childhood T acute lymphoblastic leukemia T-ALL; the T-cell signalling workhorse and CD7-positive target line. | CVCL_0065, ACH-000995 | Acute lymphoblastic leukaemia | CD7, CD3 | T-ALL; the T-cell signalling workhorse and CD7-positive target line. | none |
K-562 Blast phase chronic myelogenous leukemia, BCR-ABL1 positive CML blast crisis, BCR::ABL1 (b3a2); the original imatinib line and the CAR-T negative-control target. | CVCL_0004, ACH-000551 | BCR::ABL1 | BCR::ABL1 | CML blast crisis, BCR::ABL1 (b3a2); the original imatinib line and the CAR-T negative-control target. | none |
K-562 CD19 CD19-transduced K-562 as an artificial target with CD19-negative parent as control. | not resolved | CD19 | CD19 | CD19-transduced K-562 as an artificial target with CD19-negative parent as control. | none |
K14-Cre; Brca1; Trp53 Mammary Brca1 and Trp53 loss Basal-like tumours; the source of PARP-inhibitor resistance mechanisms (53BP1 loss, drug efflux). | none | BRCA1 / BRCA2 | none | Basal-like tumours; the source of PARP-inhibitor resistance mechanisms (53BP1 loss, drug efflux). | Liu et al., PNAS 2007 |
K14-HPV16 E6/E7 HPV16 early genes under the keratin-14 promoter, oestrogen-treated Cervical intraepithelial neoplasia to invasive carcinoma. | none | Cervical cancer | none | Cervical intraepithelial neoplasia to invasive carcinoma. | Mouse Tumor Biology database (JAX) |
| CVCL_V454 | Osteosarcoma | none | Mouse (BALB/c) metastatic osteosarcoma; syngeneic lung-metastasis model. | none | |
| CVCL_1324, ACH-000053 | ALK | ALK, CD30 | Anaplastic large-cell lymphoma, NPM1::ALK. | none | |
| CVCL_1325, ACH-000315 | Diffuse large B-cell lymphoma | EZH2 | GCB, EZH2 Y641N. | none | |
| CVCL_0589, ACH-000263 | Acute myeloid leukaemia, KIT | KIT, CD33 | RUNX1::RUNX1T1, KIT N822K; CD33-high. | none | |
| CVCL_0371, ACH-000793 | Gastric & gastro-oesophageal junction cancer | FGFR2 | FGFR2-amplified, CDH1-mutant signet-ring line. | none | |
KC Pdx1-Cre; Kras LSL-G12D PanIN precursor lesions with slow progression; used for interception and prevention studies. | none | Pancreatic ductal adenocarcinoma | none | PanIN precursor lesions with slow progression; used for interception and prevention studies. | Hingorani et al., Cancer Cell 2003 |
KCL-22 Chronic myelogenous leukemia, BCR-ABL1 positive CML line that acquires T315I under imatinib in culture. | CVCL_2091, ACH-000983 | BCR::ABL1 | BCR::ABL1 | CML line that acquires T315I under imatinib in culture. | none |
| CVCL_2092, ACH-000259 | Neuroblastoma, ALK | ALK, GD2 | MYCN-amplified, ALK F1174L. | none | |
Kit V558del knock-in Kit exon 11 deletion at the endogenous locus Caecal GIST with interstitial-cell hyperplasia; imatinib-responsive. | none | Gastrointestinal stromal tumour | none | Caecal GIST with interstitial-cell hyperplasia; imatinib-responsive. | Mouse Tumor Biology database (JAX) |
| none | KIT | none | Imatinib-responsive GIST. | Mouse Tumor Biology database (JAX) | |
| CVCL_1329, ACH-000293 | Endometrial cancer | TP53 | TP53-mutant, copy-number high (serous-like). | none | |
| CVCL_2989, ACH-000714 | Multiple myeloma, BCMA | BCMA | t(4;14) FGFR3 Y373C; TP53-null. | none | |
| none | Non-small-cell lung cancer | none | Adds p53 loss for faster, metastatic adenocarcinoma. | DuPage et al., Nat Protoc 2009 | |
KP lung and KPC pancreas Kras G12D; Trp53 Low mutation burden and immune-cold; used to model checkpoint resistance rather than response. | none | PD-1 | none | Low mutation burden and immune-cold; used to model checkpoint resistance rather than response. | DuPage et al., Nat Protoc 2009 |
KPC Pdx1-Cre; Kras LSL-G12D; Trp53 LSL-R172H The reference PDAC model: stroma-rich, metastatic, immune-excluded; median survival about 5 months. | none | Pancreatic ductal adenocarcinoma | none | The reference PDAC model: stroma-rich, metastatic, immune-excluded; median survival about 5 months. | Hingorani et al., Cancer Cell 2005 |
KPC-derived lines Murine lines from the KPC GEMM (Kras G12D; Trp53 R172H) used for syngeneic immunotherapy studies. | not resolved | Pancreatic ductal adenocarcinoma, PD-1 | KRAS, PD-1 | Murine lines from the KPC GEMM (Kras G12D; Trp53 R172H) used for syngeneic immunotherapy studies. | none |
Kras LSL-G12C Conditional G12C allele Lung tumours that respond to covalent G12C inhibitors, enabling immunocompetent combination studies. | none | KRAS | none | Lung tumours that respond to covalent G12C inhibitors, enabling immunocompetent combination studies. | Canon et al., Nature 2019 |
Kras LSL-G12D Conditional G12D allele used across lung, pancreas and colon models The founding conditional Kras allele. | none | KRAS | none | The founding conditional Kras allele. | Jackson et al., Genes Dev 2001 |
Kras LSL-G12D (K) Kras G12D activated by inhaled Cre Adenomas progressing to adenocarcinoma; the base model for lung GEMMs. | none | Non-small-cell lung cancer | none | Adenomas progressing to adenocarcinoma; the base model for lung GEMMs. | Jackson et al., Genes Dev 2001 |
| CVCL_0379, ACH-000074 | BCR::ABL1 | BCR::ABL1 | CML basophilic line, BCR::ABL1. | none | |
Kuramochi High grade ovarian serous adenocarcinoma Ranked among the most HGSOC-like lines (TP53, BRCA2 mutant, KRAS amplification). | CVCL_1345, ACH-000524 | Ovarian cancer | BRCA1 / BRCA2, TP53 | Ranked among the most HGSOC-like lines (TP53, BRCA2 mutant, KRAS amplification). | none |
| CVCL_1348, ACH-000855 | Oesophageal cancer | EGFR | Oesophageal squamous carcinoma; EGFR-expressing. | none | |
| CVCL_1351, ACH-000777 | Oesophageal cancer | EGFR | Oesophageal squamous carcinoma, EGFR-amplified. | none | |
L2-IL1β Interleukin-1beta under the Epstein-Barr L2 promoter Barrett's-like metaplasia progressing to adenocarcinoma with bile acid; the main Barrett's GEMM. | none | Oesophageal cancer | none | Barrett's-like metaplasia progressing to adenocarcinoma with bile acid; the main Barrett's GEMM. | Quante et al., Cancer Cell 2012 |
| CVCL_4744 | Prostate cancer, Androgen receptor | Androgen receptor | Wild-type AR, androgen-dependent. | none | |
| CVCL_4358 | PD-1 | PD-1 | Lewis lung carcinoma; refractory. | none | |
| CVCL_0393, ACH-000595 | Glioma & glioblastoma | none | TP53-mutant, PTEN wild-type. | none | |
LNCaP Prostate carcinoma AR T878A, PTEN-null, PSMA-high; androgen-sensitive. The parent of C4-2 and C4-2B castration-resistant sublines. | CVCL_0395 | Prostate cancer, Androgen receptor, PSMA | Androgen receptor, PSMA, AKT | AR T878A, PTEN-null, PSMA-high; androgen-sensitive. The parent of C4-2 and C4-2B castration-resistant sublines. | none |
| CVCL_0399, ACH-000950 | Colorectal cancer | KRAS | KRAS G13D, MSI-high. | none | |
| CVCL_0397, ACH-000957 | Colorectal cancer, KRAS | KRAS | KRAS G12D, MSI-high. | none | |
LuCaP PDX series (University of Washington) The largest prostate PDX collection, including AR-V7-high and neuroendocrine lines, shared by material transfer agreement. | none | Androgen receptor | none | The largest prostate PDX collection, including AR-V7-high and neuroendocrine lines, shared by material transfer agreement. | portal |
Math1-Cre; SmoM2 Constitutively active Smoothened in granule-neuron precursors Fully penetrant SHH medulloblastoma; used for vismodegib resistance. | none | Medulloblastoma | none | Fully penetrant SHH medulloblastoma; used for vismodegib resistance. | Mouse Tumor Biology database (JAX) |
MB49 Mouse bladder transitional cell carcinoma Mouse (C57BL/6) syngeneic bladder line; intravesical immunotherapy model. | CVCL_7076 | Bladder & urothelial cancer | PD-1 | Mouse (C57BL/6) syngeneic bladder line; intravesical immunotherapy model. | none |
MC38 Mouse colon adenocarcinoma Mouse (C57BL/6) MSI-like, immunogenic colon line; the most used syngeneic checkpoint-inhibitor model. | CVCL_B288 | Colorectal cancer, PD-1 | PD-1, PD-L1 | Mouse (C57BL/6) MSI-like, immunogenic colon line; the most used syngeneic checkpoint-inhibitor model. | none |
MCF-7 Invasive breast carcinoma of no special type ER-positive luminal A, PIK3CA E545K; the reference line for endocrine therapy and CDK4/6 inhibitors. | CVCL_0031, ACH-000019 | HR-positive / HER2-negative breast cancer, HER2, Estrogen receptor, TP53 | Estrogen receptor, PIK3CA / PI3K-alpha, CDK4/6, HER2, TP53, MDM2 | ER-positive luminal A, PIK3CA E545K; the reference line for endocrine therapy and CDK4/6 inhibitors. | none |
| CVCL_4748, ACH-000952 | Androgen receptor | Androgen receptor | T878A and L702H double mutant. | none | |
| CVCL_0617, ACH-000044 | Estrogen receptor | Estrogen receptor | ER-positive lobular carcinoma line. | none | |
MDA-MB-231 Breast adenocarcinoma Mesenchymal-like TNBC, KRAS G13D, BRAF G464V; highly metastatic in mice. | CVCL_0062, ACH-000768 | Triple-negative breast cancer, BRAF, TROP2 | KRAS, BRAF, TROP2 | Mesenchymal-like TNBC, KRAS G13D, BRAF G464V; highly metastatic in mice. | none |
| CVCL_0620, ACH-000934 | HR-positive / HER2-negative breast cancer | Estrogen receptor, HER2, PIK3CA / PI3K-alpha | ER-positive, HER2-amplified, PIK3CA E545K. | none | |
| CVCL_0623, ACH-000573 | Triple-negative breast cancer, BRCA1 / BRCA2 | BRCA1 / BRCA2, PARP | BRCA1-mutant; PARP-inhibitor sensitive. | none | |
MDA-MB-453 Breast adenocarcinoma Breast, HER2-low (IHC 1+ to 2+); used for HER2-low ADC bystander studies. | CVCL_0418, ACH-000910 | HER2 | HER2 | Breast, HER2-low (IHC 1+ to 2+); used for HER2-low ADC bystander studies. | none |
| CVCL_0419, ACH-000849 | Triple-negative breast cancer, TP53, TROP2 | TROP2, TP53, EGFR | Basal-like, EGFR-amplified, PTEN-null, TP53 R273H; TROP2-high. | none | |
MEC-1 Chronic lymphocytic leukemia CLL-derived line in prolymphocytoid transformation; TP53-mutant; the most used CLL line. | CVCL_1870, ACH-000405 | Chronic lymphocytic leukaemia, BTK | BTK | CLL-derived line in prolymphocytoid transformation; TP53-mutant; the most used CLL line. | none |
| CVCL_0426, ACH-000359 | Osteosarcoma | TP53 | TP53-null, CDKN2A-deleted. | none | |
| CVCL_0428, ACH-000601 | Pancreatic ductal adenocarcinoma, KRAS | KRAS | KRAS G12C; one of the few G12C pancreatic lines. | none | |
| CVCL_0434, ACH-000356 | Gastric & gastro-oesophageal junction cancer | MET | MET-amplified; capmatinib and MET ADC model. | none | |
MLL-AF9 retroviral Retroviral MLL-AF9 in haematopoietic progenitors transplanted into recipients Rapid, transplantable AML that defined leukaemia stem-cell biology. | none | Acute myeloid leukaemia | none | Rapid, transplantable AML that defined leukaemia stem-cell biology. | Krivtsov et al., Nature 2006 |
| CVCL_8792, ACH-000763 | Multiple myeloma, BCMA | BCMA, GPRC5D, CD38 | Dexamethasone-sensitive; BCMA-high; the standard CAR-T and bispecific line. | none | |
MMTV-Neu Rat Neu (Erbb2) under the MMTV promoter HER2-driven mammary tumours; used for anti-HER2 antibody and vaccine work. | none | HER2-positive breast cancer | none | HER2-driven mammary tumours; used for anti-HER2 antibody and vaccine work. | Guy et al., PNAS 1992 |
| none | HER2 | none | HER2-driven mammary tumours. | Guy et al., PNAS 1992 | |
MMTV-PyMT Polyoma middle T under the MMTV promoter Fast luminal-like tumours with lung metastases; ER expression is lost with progression. | none | HR-positive / HER2-negative breast cancer | none | Fast luminal-like tumours with lung metastases; ER expression is lost with progression. | Guy et al., Mol Cell Biol 1992 |
MOC1 Squamous cell carcinoma of the mouse oral cavity Mouse (C57BL/6) carcinogen-induced oral SCC; immunogenic syngeneic model. | CVCL_ZD32 | Head and neck squamous cell carcinoma | PD-1 | Mouse (C57BL/6) carcinogen-induced oral SCC; immunogenic syngeneic model. | none |
MOLM-13 Adult acute monocytic leukemia FLT3-ITD, MLL-AF9 (KMT2A::MLLT3); the standard FLT3 and menin inhibitor line. | CVCL_2119, ACH-000362 | Acute myeloid leukaemia, FLT3 | FLT3, KMT2A, Menin | FLT3-ITD, MLL-AF9 (KMT2A::MLLT3); the standard FLT3 and menin inhibitor line. | none |
| CVCL_7916, ACH-001574 | FLT3 | FLT3 | ITD; sister line of MOLM-13. | none | |
| CVCL_1430, ACH-000335 | Mesothelioma | Mesothelin | Biphasic mesothelioma; CDKN2A-deleted. | none | |
| CVCL_0064, ACH-000045 | Acute myeloid leukaemia, FLT3 | FLT3, KMT2A, Menin | FLT3-ITD homozygous, MLL-AF4; highly FLT3-dependent. | none | |
| CVCL_A656 | Thyroid cancer | RET | Medullary carcinoma, RET M918T. | none | |
NALM-6 Adult B acute lymphoblastic leukemia Pre-B ALL, DUX4-rearranged; CD19- and CD22-positive; the CD19 CAR-T reference line. | CVCL_0092, ACH-000938 | Acute lymphoblastic leukaemia, CD19 | CD19, CD22 | Pre-B ALL, DUX4-rearranged; CD19- and CD22-positive; the CD19 CAR-T reference line. | none |
| CVCL_1440, ACH-000804 | Neuroblastoma, ALK | ALK | ALK-amplified. | none | |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Non-small-cell lung cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Small-cell lung cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | HR-positive / HER2-negative breast cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | HER2-positive breast cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Triple-negative breast cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Colorectal cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Colorectal cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Pancreatic ductal adenocarcinoma | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Pancreatic ductal adenocarcinoma | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Prostate cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Melanoma | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Glioma & glioblastoma | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Ovarian cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Gastric & gastro-oesophageal junction cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Hepatocellular carcinoma | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Acute myeloid leukaemia | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Bladder & urothelial cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Renal cell carcinoma | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Head and neck squamous cell carcinoma | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Neuroblastoma | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Ewing sarcoma | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Osteosarcoma | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Mesothelioma | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Biliary tract cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Endometrial cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Cervical cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Oesophageal cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Thyroid cancer | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Medulloblastoma | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | KRAS | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | EGFR | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | HER2 | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | BRAF | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | ALK | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Estrogen receptor | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | TP53 | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | BRCA1 / BRCA2 | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | IDH1 / IDH2 | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | Androgen receptor | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
NCI Patient-Derived Models Repository (PDMR) Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | none | TROP2 | none | Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing. | portal |
| CVCL_0060, ACH-000510 | TP53 | TP53 | TP53-null lung line used to re-express mutant alleles. | none | |
NCI-H146 Lung small cell carcinoma ASCL1 subtype, DLL3-expressing; used for tarlatamab and rovalpituzumab work. | CVCL_1473, ACH-000506 | Small-cell lung cancer | DLL3 | ASCL1 subtype, DLL3-expressing; used for tarlatamab and rovalpituzumab work. | none |
NCI-H1650 Minimally invasive lung adenocarcinoma Exon 19 deletion with PTEN loss; intrinsically TKI-resistant. | CVCL_1483, ACH-000035 | EGFR | EGFR | Exon 19 deletion with PTEN loss; intrinsically TKI-resistant. | none |
| CVCL_1511, ACH-000587 | Non-small-cell lung cancer, EGFR, TROP2 | EGFR, TROP2 | EGFR L858R plus T790M; the osimertinib development line. | none | |
| CVCL_1518, ACH-000153 | Mesothelioma | none | Sarcomatoid-like, NF2-mutant. | none | |
| CVCL_1543, ACH-000447 | Non-small-cell lung cancer, ALK | ALK | EML4-ALK variant 3. | none | |
NCI-H226 Pleural epithelioid mesothelioma Epithelioid, mesothelin-high; the mesothelin CAR-T and ADC standard. | CVCL_1544, ACH-000367 | Mesothelioma | Mesothelin | Epithelioid, mesothelin-high; the mesothelin CAR-T and ADC standard. | none |
| CVCL_1547, ACH-000900 | Non-small-cell lung cancer, KRAS | KRAS | KRAS G12C, TP53 mutant. | none | |
| CVCL_1555, ACH-000648 | Mesothelioma | none | BAP1-mutant epithelioid line. | none | |
| CVCL_5160, ACH-000337 | Non-small-cell lung cancer, ALK | ALK | EML4-ALK variant 1 adenocarcinoma. | none | |
| CVCL_6831, ACH-000109 | EGFR | EGFR | L858R with amplification. | none | |
NCI-H358 Minimally invasive lung adenocarcinoma KRAS G12C adenocarcinoma; the workhorse line for sotorasib and adagrasib pharmacology. | CVCL_1559, ACH-000860 | Non-small-cell lung cancer, KRAS | KRAS | KRAS G12C adenocarcinoma; the workhorse line for sotorasib and adagrasib pharmacology. | none |
| CVCL_0459, ACH-000463 | Non-small-cell lung cancer, KRAS | KRAS | KRAS Q61H large-cell carcinoma. | none | |
NCI-H660 Prostate small cell carcinoma Neuroendocrine prostate cancer line; AR-negative, DLL3-positive. | CVCL_1576, ACH-000177 | Prostate cancer | DLL3 | Neuroendocrine prostate cancer line; AR-negative, DLL3-positive. | none |
| CVCL_1579, ACH-000358 | Small-cell lung cancer | none | Classic (ASCL1-high) SCLC; grows as floating aggregates. | none | |
| CVCL_1591, ACH-000355 | Small-cell lung cancer | none | Variant (NEUROD1/MYC-driven) SCLC. | none | |
| CVCL_1600, ACH-000050 | Multiple myeloma, BCMA | BCMA, GPRC5D | t(4;14), NRAS G13D; BCMA and GPRC5D expressing. | none | |
NCI-N87 Gastric tubular adenocarcinoma HER2-amplified gastric adenocarcinoma; the T-DXd and zanidatamab xenograft standard. | CVCL_1603, ACH-000427 | Gastric & gastro-oesophageal junction cancer, HER2 | HER2 | HER2-amplified gastric adenocarcinoma; the T-DXd and zanidatamab xenograft standard. | none |
| CVCL_1612, ACH-000911 | TP53 | TP53 | Y220C gastric line. | none | |
OCI-AML3 Adult acute myelomonocytic leukemia NPM1c, DNMT3A R882C; the NPM1-mutant menin inhibitor model. | CVCL_1844, ACH-000336 | Acute myeloid leukaemia | NPM1 mutation, Menin | NPM1c, DNMT3A R882C; the NPM1-mutant menin inhibitor model. | none |
| CVCL_1879 | Diffuse large B-cell lymphoma | BCL-2, EZH2 | GCB, BCL2-translocated, EZH2 Y641N. | none | |
| CVCL_8795, ACH-001146 | Diffuse large B-cell lymphoma, BTK | BTK | ABC, MYD88 L265P; ibrutinib-sensitive. | none | |
OCI-LY3 Diffuse large B-cell lymphoma activated B-cell type ABC, CARD11 and MYD88 L265P; NF-kB dependent. | CVCL_8800, ACH-000158 | Diffuse large B-cell lymphoma | none | ABC, CARD11 and MYD88 L265P; NF-kB dependent. | none |
| CVCL_1622, ACH-000679 | Oesophageal cancer, HER2 | HER2 | Junctional adenocarcinoma, HER2-amplified. | none | |
| CVCL_0471, ACH-000383 | Oesophageal cancer | HER2, TP53 | Oesophageal adenocarcinoma, HER2-amplified, TP53-mutant. | none | |
Organoid-derived orthotopic (AKP) Apc; Kras G12D; Trp53 engineered organoids transplanted into the colon Invasive, metastatic colon cancer in weeks; combines GEMM genetics with organoid speed. | none | Colorectal cancer | none | Invasive, metastatic colon cancer in weeks; combines GEMM genetics with organoid speed. | O'Rourke et al., Nat Biotechnol 2017 |
| CVCL_Y382 | Chronic lymphocytic leukaemia | BTK | EBV-transformed CLL line from Ohio State. | none | |
Osx-Cre; Trp53; Rb1 Osteoblast-lineage deletion of Trp53 and Rb1 Highly penetrant, metastatic osteosarcoma resembling the human disease. | none | Osteosarcoma | none | Highly penetrant, metastatic osteosarcoma resembling the human disease. | Walkley et al., Genes Dev 2008 |
OVCAR-3 High grade ovarian serous adenocarcinoma High-grade serous, TP53 R248Q, CCNE1-amplified; platinum-resistant patient. | CVCL_0465, ACH-000001 | Ovarian cancer | TP53 | High-grade serous, TP53 R248Q, CCNE1-amplified; platinum-resistant patient. | none |
| CVCL_1629, ACH-000696 | Ovarian cancer | none | High-grade serous-like; used in NCI-60. | none | |
| CVCL_0480, ACH-000164 | Pancreatic ductal adenocarcinoma, KRAS | KRAS, TP53 | KRAS G12D, TP53 R273H, CDKN2A-null; quasi-mesenchymal. | none | |
PC-3 Prostate carcinoma AR-negative, PSMA-negative, PTEN-null; used as the negative control and (engineered PC-3 PIP) as a PSMA-positive pair. | CVCL_0035, ACH-000090 | Prostate cancer, PSMA | PSMA | AR-negative, PSMA-negative, PTEN-null; used as the negative control and (engineered PC-3 PIP) as a PSMA-positive pair. | none |
PC-9 Lung adenocarcinoma EGFR exon 19 deletion; used for every generation of EGFR TKI and for persister biology. | CVCL_B260, ACH-000779 | Non-small-cell lung cancer, EGFR | EGFR | EGFR exon 19 deletion; used for every generation of EGFR TKI and for persister biology. | none |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Non-small-cell lung cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Small-cell lung cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Small-cell lung cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | HR-positive / HER2-negative breast cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | HER2-positive breast cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Triple-negative breast cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Colorectal cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Pancreatic ductal adenocarcinoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Prostate cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Prostate cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Melanoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Melanoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Glioma & glioblastoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Glioma & glioblastoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Ovarian cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Gastric & gastro-oesophageal junction cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Hepatocellular carcinoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Hepatocellular carcinoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Acute myeloid leukaemia | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Chronic lymphocytic leukaemia | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Diffuse large B-cell lymphoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Multiple myeloma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Acute lymphoblastic leukaemia | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Bladder & urothelial cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Bladder & urothelial cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Renal cell carcinoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Renal cell carcinoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Head and neck squamous cell carcinoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Neuroblastoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Neuroblastoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Ewing sarcoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Osteosarcoma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Mesothelioma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Mesothelioma | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Biliary tract cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Biliary tract cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Gastrointestinal stromal tumour | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Endometrial cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Cervical cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Oesophageal cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Thyroid cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Thyroid cancer | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | KRAS | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | EGFR | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | HER2 | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | BRAF | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | ALK | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Estrogen receptor | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | TP53 | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | BRCA1 / BRCA2 | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | IDH1 / IDH2 | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | KIT | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | FLT3 | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | BCR::ABL1 | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | BTK | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Androgen receptor | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | Androgen receptor | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | PSMA | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | TROP2 | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | CD19 | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PDCM Finder (cancermodels.org) EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | none | BCMA | none | EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers. | portal |
PEO1 BRCA2 syndrome BRCA2-mutant; PEO4 from the same patient carries a BRCA2 reversion, an isogenic PARP-inhibitor resistance pair. | CVCL_2686, ACH-001630 | Ovarian cancer, BRCA1 / BRCA2 | BRCA1 / BRCA2, PARP | BRCA2-mutant; PEO4 from the same patient carries a BRCA2 reversion, an isogenic PARP-inhibitor resistance pair. | none |
PRoXe (Public Repository of Xenografts) Dana-Farber bank of leukaemia and lymphoma patient-derived xenografts. | none | Acute myeloid leukaemia | none | Dana-Farber bank of leukaemia and lymphoma patient-derived xenografts. | portal |
PRoXe (Public Repository of Xenografts) Dana-Farber bank of leukaemia and lymphoma patient-derived xenografts. | none | Diffuse large B-cell lymphoma | none | Dana-Farber bank of leukaemia and lymphoma patient-derived xenografts. | portal |
PRoXe (Public Repository of Xenografts) Dana-Farber bank of leukaemia and lymphoma patient-derived xenografts. | none | Acute lymphoblastic leukaemia | none | Dana-Farber bank of leukaemia and lymphoma patient-derived xenografts. | portal |
PRoXe (Public Repository of Xenografts) Dana-Farber bank of leukaemia and lymphoma patient-derived xenografts. | none | FLT3 | none | Dana-Farber bank of leukaemia and lymphoma patient-derived xenografts. | portal |
PRoXe (Public Repository of Xenografts) Dana-Farber bank of leukaemia and lymphoma patient-derived xenografts. | none | CD19 | none | Dana-Farber bank of leukaemia and lymphoma patient-derived xenografts. | portal |
Ptch1 +/- Heterozygous Patched-1 loss SHH-subgroup medulloblastoma in about 15% of mice; the founding SHH model. | none | Medulloblastoma | none | SHH-subgroup medulloblastoma in about 15% of mice; the founding SHH model. | Goodrich et al., Science 1997 |
Pten / Trp53 PB-Cre4; Pten flox; Trp53 flox Lethal, invasive disease with lineage plasticity under castration. | none | Prostate cancer | none | Lethal, invasive disease with lineage plasticity under castration. | Chen et al., Nature 2005 |
Pten conditional PB-Cre4; Pten flox/flox Invasive adenocarcinoma with slow progression; models the commonest human lesion. | none | Prostate cancer | none | Invasive adenocarcinoma with slow progression; models the commonest human lesion. | Wang et al., Cancer Cell 2003 |
Pten conditional Progesterone-receptor-Cre; Pten flox Endometrial hyperplasia to carcinoma; models the commonest human lesion. | none | Endometrial cancer | none | Endometrial hyperplasia to carcinoma; models the commonest human lesion. | Mouse Tumor Biology database (JAX) |
| none | Androgen receptor | none | AR-dependent adenocarcinoma responsive to castration. | Wang et al., Cancer Cell 2003 | |
| CVCL_0511, ACH-000654 | Diffuse large B-cell lymphoma, CD19 | CD19, CD20 | Burkitt line used for CD19 and CD20 targeting; CD19 CAR-T standard. | none | |
RBE Intrahepatic cholangiocarcinoma Intrahepatic with IDH1 R132S; the ivosidenib cholangiocarcinoma line. | CVCL_4896, ACH-001856 | Biliary tract cancer, IDH1 / IDH2 | IDH1 / IDH2 | Intrahepatic with IDH1 R132S; the ivosidenib cholangiocarcinoma line. | none |
RCAS / tv-a Somatic delivery of PDGFB, Kras or other oncogenes to Nestin- or GFAP-expressing cells Flexible somatic model reproducing proneural and other subtypes. | none | Glioma & glioblastoma | none | Flexible somatic model reproducing proneural and other subtypes. | Holland et al., Nat Genet 2000 |
| CVCL_1884, ACH-000068 | BTK | BTK | Mantle-cell lymphoma, ibrutinib-sensitive. | none | |
| CVCL_1650, ACH-000960 | Acute lymphoblastic leukaemia, CD19 | CD19 | ETV6::RUNX1 pre-B ALL. | none | |
RENCA Mouse kidney carcinoma Mouse (BALB/c) renal carcinoma; syngeneic immunotherapy model, not VHL-driven. | CVCL_2174 | Renal cell carcinoma | PD-1 | Mouse (BALB/c) renal carcinoma; syngeneic immunotherapy model, not VHL-driven. | none |
Retroviral BCR-ABL bone-marrow transplant p210 BCR-ABL1 in transplanted marrow CML-like myeloproliferation in weeks; the standard for kinase-inhibitor and stem-cell studies. | none | BCR::ABL1 | none | CML-like myeloproliferation in weeks; the standard for kinase-inhibitor and stem-cell studies. | Mouse Tumor Biology database (JAX) |
| CVCL_0504, ACH-000943 | Colorectal cancer, BRAF | BRAF | BRAF V600E, MSI-high, CIMP-high. | none | |
| none | Small-cell lung cancer | none | The original SCLC GEMM; long latency (about 9 months). | Meuwissen et al., Cancer Cell 2003 | |
| none | Small-cell lung cancer | none | Fast, MYC-driven variant subtype; models NEUROD1 transition. | Mollaoglu et al., Cancer Cell 2017 | |
| CVCL_0014, ACH-000817 | Multiple myeloma, BCMA | BCMA, CD38 | BCMA-positive; used for belantamab and proteasome-inhibitor resistance. | none | |
| CVCL_0093, ACH-000874 | Acute lymphoblastic leukaemia | KMT2A, BCL-2, CD19 | KMT2A::AFF1, BCL2-dependent. | none | |
| CVCL_1670, ACH-000473 | Bladder & urothelial cancer | FGFR2 | FGFR3::TACC3, luminal papillary. | none | |
| CVCL_0036, ACH-000242 | Bladder & urothelial cancer | FGFR2 | FGFR3::TACC3 fusion, low grade; erdafitinib model. | none | |
Sanger Cell Model Passports Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | none | Non-small-cell lung cancer | none | Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | portal |
Sanger Cell Model Passports Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | none | HR-positive / HER2-negative breast cancer | none | Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | portal |
Sanger Cell Model Passports Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | none | HER2-positive breast cancer | none | Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | portal |
Sanger Cell Model Passports Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | none | Triple-negative breast cancer | none | Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | portal |
Sanger Cell Model Passports Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | none | Colorectal cancer | none | Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | portal |
Sanger Cell Model Passports Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | none | Pancreatic ductal adenocarcinoma | none | Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | portal |
Sanger Cell Model Passports Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | none | Ovarian cancer | none | Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | portal |
Sanger Cell Model Passports Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | none | Gastric & gastro-oesophageal junction cancer | none | Genomic and phenotypic passports for over 2,000 cell lines and organoids, including the Sanger organoid collection. | portal |
| CVCL_0548, ACH-000410 | Osteosarcoma, TP53 | TP53 | TP53-null, RB1-null; osteoblastic. | none | |
| CVCL_0095, ACH-000782 | Acute lymphoblastic leukaemia | KMT2A, Menin, CD19 | KMT2A::AFF1 (MLL-AF4) infant ALL; menin inhibitor model. | none | |
| CVCL_0019, ACH-001188 | Neuroblastoma, ALK | ALK, GD2 | ALK F1174L, MYCN non-amplified subclone of SK-N-SH; GD2-positive. | none | |
| CVCL_0032, ACH-000556 | Cervical cancer | none | HPV16 squamous carcinoma. | none | |
| CVCL_1697, ACH-000748 | TP53 | MDM2, TP53 | MDM2-amplified osteosarcoma; the MDM2-inhibitor standard. | none | |
| CVCL_0033, ACH-000017 | HER2-positive breast cancer, HER2, TP53 | HER2, TP53 | HER2-amplified, ER-negative; trastuzumab-sensitive. | none | |
| CVCL_0069, ACH-001190 | Melanoma | none | NRAS Q61R; the MEK-inhibitor and NRAS control. | none | |
| CVCL_0526, ACH-000615 | Melanoma, BRAF | BRAF, CDK4/6 | BRAF V600E, CDK4 R24C. | none | |
| CVCL_1700, ACH-000260 | Neuroblastoma | none | MYCN non-amplified, NRAS Q61K. | none | |
| CVCL_0530, ACH-000039 | Ewing sarcoma | EWSR1-FLI1 fusion | EWSR1::FLI1 (misclassified historically as neuroblastoma). | none | |
SK-OV-3 Ovarian serous cystadenocarcinoma TP53-null, PIK3CA H1047R, HER2-expressing; widely used and not serous-like. | CVCL_0532, ACH-000811 | Ovarian cancer | PIK3CA / PI3K-alpha, HER2 | TP53-null, PIK3CA H1047R, HER2-expressing; widely used and not serous-like. | none |
| CVCL_5008, ACH-000209 | IDH1 / IDH2 | IDH1 / IDH2 | Cholangiocarcinoma, IDH1 R132C. | none | |
| CVCL_0076, ACH-000581 | Gastric & gastro-oesophageal junction cancer | FGFR2 | FGFR2-amplified; bemarituzumab model. | none | |
| CVCL_0454, ACH-000420 | Hepatocellular carcinoma | none | Mesenchymal-like, GPC3-low HCC. | none | |
SNU-601 Gastric signet ring cell adenocarcinoma CLDN18.2-expressing; used for zolbetuximab and CLDN18.2 ADCs. | CVCL_0101, ACH-000736 | Gastric & gastro-oesophageal junction cancer | Claudin 18.2 | CLDN18.2-expressing; used for zolbetuximab and CLDN18.2 ADCs. | none |
| CVCL_0538, ACH-000664 | ALK | ALK, CD30 | Anaplastic large-cell lymphoma, NPM1::ALK. | none | |
SU-DHL-4 Diffuse large B-cell lymphoma germinal center B-cell type GCB, BCL2-translocated; venetoclax and CD20 antibody model. | CVCL_0539, ACH-000365 | Diffuse large B-cell lymphoma | BCL-2, CD20, CD19 | GCB, BCL2-translocated; venetoclax and CD20 antibody model. | none |
SU-DHL-6 Diffuse large B-cell lymphoma germinal center B-cell type GCB, EZH2 Y641N; tazemetostat model. | CVCL_2206, ACH-000611 | Diffuse large B-cell lymphoma | EZH2, CD20 | GCB, EZH2 Y641N; tazemetostat model. | none |
| CVCL_3422, ACH-001390 | Triple-negative breast cancer, BRCA1 / BRCA2 | BRCA1 / BRCA2, PARP | BRCA1-mutant inflammatory breast cancer line. | none | |
SUP-B15 Childhood B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2) BCR-ABL1 BCR::ABL1 (p190) Ph-positive ALL. | CVCL_0103, ACH-000059 | Acute lymphoblastic leukaemia, BCR::ABL1 | BCR::ABL1, CD19 | BCR::ABL1 (p190) Ph-positive ALL. | none |
| CVCL_0543, ACH-000418 | IDH1 / IDH2 | IDH1 / IDH2 | Chondrosarcoma, IDH2 R172S. | none | |
| CVCL_1720, ACH-000677 | KRAS | KRAS | Lung, G12C. | none | |
| CVCL_0546, ACH-000842 | Colorectal cancer, KRAS | KRAS, TP53 | KRAS G12V, TP53 R273H/P309S, APC-truncated; MSS. | none | |
SW620 Colon adenocarcinoma Lymph-node metastasis from the same patient as SW480; matched primary-metastasis pair. | CVCL_0547, ACH-000651 | Colorectal cancer | KRAS | Lymph-node metastasis from the same patient as SW480; matched primary-metastasis pair. | none |
T-47D Invasive breast carcinoma of no special type ER-positive, PIK3CA H1047R, progesterone-receptor high. | CVCL_0553, ACH-000147 | HR-positive / HER2-negative breast cancer, Estrogen receptor | Estrogen receptor, PIK3CA / PI3K-alpha, CDK4/6 | ER-positive, PIK3CA H1047R, progesterone-receptor high. | none |
| CVCL_0554, ACH-000018 | Bladder & urothelial cancer | TP53 | HRAS G12V, TP53 mutant; basal-like. | none | |
| CVCL_0556, ACH-000571 | Glioma & glioblastoma | none | Hyperpentaploid, temozolomide-resistant (MGMT-positive). | none | |
TC-1 Mouse (C57BL/6) HPV16 E6/E7-transformed lung epithelial line; the standard HPV therapeutic-vaccine model. | CVCL_4699 | Cervical cancer | PD-1 | Mouse (C57BL/6) HPV16 E6/E7-transformed lung epithelial line; the standard HPV therapeutic-vaccine model. | none |
| CVCL_2213, ACH-000424 | Ewing sarcoma | EWSR1-FLI1 fusion, TP53 | EWSR1::FLI1 type 1, TP53 R213X. | none | |
TH-ALK F1174L; TH-MYCN Mutant ALK co-expressed with MYCN Accelerated, lethal disease showing ALK-MYCN co-operation. | none | Neuroblastoma | none | Accelerated, lethal disease showing ALK-MYCN co-operation. | Berry et al., Cancer Cell 2012 |
TH-MYCN MYCN under the tyrosine hydroxylase promoter Sympathoadrenal tumours in weeks (homozygous); the standard neuroblastoma GEMM. | none | Neuroblastoma | none | Sympathoadrenal tumours in weeks (homozygous); the standard neuroblastoma GEMM. | Weiss et al., EMBO J 1997 |
| CVCL_0006, ACH-000146 | Acute myeloid leukaemia | KMT2A, CD123 | MLL-AF9 monocytic line; CD123-expressing. | none | |
TMD8 Diffuse large B-cell lymphoma activated B-cell type ABC, CD79B Y196 and MYD88 L265P; the reference BTK-inhibitor line. | CVCL_A442 | Diffuse large B-cell lymphoma, BTK | BTK, CD79b | ABC, CD79B Y196 and MYD88 L265P; the reference BTK-inhibitor line. | none |
TPC-1 Thyroid gland papillary carcinoma Papillary carcinoma with CCDC6::RET fusion; the RET inhibitor line. | CVCL_6298 | Thyroid cancer | RET | Papillary carcinoma with CCDC6::RET fusion; the RET inhibitor line. | none |
TPO-Cre; Braf V600E Thyroid-specific Braf V600E Papillary carcinoma with loss of iodine uptake, restored by MAPK inhibition (the basis of redifferentiation trials). | none | Thyroid cancer | none | Papillary carcinoma with loss of iodine uptake, restored by MAPK inhibition (the basis of redifferentiation trials). | Mouse Tumor Biology database (JAX) |
| none | Prostate cancer | none | Aggressive, often neuroendocrine tumours; historic immunotherapy model. | Greenberg et al., PNAS 1995 | |
Trp53 R172H and R270H knock-ins Murine equivalents of human R175H and R273H Gain-of-function alleles with a metastatic phenotype beyond simple loss. | none | TP53 | none | Gain-of-function alleles with a metastatic phenotype beyond simple loss. | Olive et al., Cell 2004 |
| CVCL_A5HW | IDH1 / IDH2 | IDH1 / IDH2 | Glioma, IDH1 R132H neurosphere culture. | none | |
TT Hereditary thyroid gland medullary carcinoma Medullary carcinoma, RET C634W; the selpercatinib and vandetanib model. | CVCL_1774, ACH-001321 | Thyroid cancer | RET | Medullary carcinoma, RET C634W; the selpercatinib and vandetanib model. | none |
Tumour-organoid and autologous T-cell co-cultures Patient organoids co-cultured with peripheral blood T cells to test checkpoint blockade per patient (Dijkstra et al., Cell 2018). | none | PD-1 | none | Patient organoids co-cultured with peripheral blood T cells to test checkpoint blockade per patient (Dijkstra et al., Cell 2018). | portal |
| CVCL_0021, ACH-000232 | Glioma & glioblastoma | TP53 | TP53 R273H, PTEN-null; invasive in orthotopic models. | none | |
U-87MG ATCC Glioblastoma The most cited glioma line; of uncertain origin (not the original Uppsala U-87MG) and poorly representative of GBM. | CVCL_0022, ACH-000075 | Glioma & glioblastoma | none | The most cited glioma line; of uncertain origin (not the original Uppsala U-87MG) and poorly representative of GBM. | none |
| CVCL_0566, ACH-000626 | Multiple myeloma, BCMA | BCMA | IL-6 autocrine line; BCMA-low relative to MM.1S. | none | |
U2OS Osteosarcoma TP53 wild-type, RB1 wild-type, ATRX-null; more a cell-biology tool than a disease model. | CVCL_0042, ACH-000364 | Osteosarcoma | none | TP53 wild-type, RB1 wild-type, ATRX-null; more a cell-biology tool than a disease model. | none |
| CVCL_7759 | Head and neck squamous cell carcinoma | none | HPV16-positive oral SCC. | none | |
| CVCL_1783, ACH-000522 | Bladder & urothelial cancer | KRAS, Nectin-4 | KRAS G12C, basal, Nectin-4 expressing. | none | |
| none | Bladder & urothelial cancer | none | Invasive urothelial carcinoma. | Puzio-Kuter et al., Genes Dev 2009 | |
| CVCL_B079, ACH-001418 | Ovarian cancer, BRCA1 / BRCA2 | BRCA1 / BRCA2, PARP | BRCA1-null line with a BRCA1-restored derivative. | none | |
| CVCL_2235, ACH-000115 | Prostate cancer, Androgen receptor | Androgen receptor | AR-amplified, TMPRSS2-ERG fusion, wild-type AR ligand-binding domain. | none | |
Vhl / Trp53 / Rb1 Ksp1.3-CreERT2; Vhl; Trp53; Rb1 flox Clear-cell RCC arising from proximal tubule in mice, which single Vhl loss does not produce. | none | Renal cell carcinoma | none | Clear-cell RCC arising from proximal tubule in mice, which single Vhl loss does not produce. | Harlander et al., Nat Med 2017 |
Vk*MYC Sporadic MYC activation in germinal-centre B cells Indolent monoclonal gammopathy progressing to myeloma in old mice; predicts single-agent clinical activity unusually well. | none | Multiple myeloma | none | Indolent monoclonal gammopathy progressing to myeloma in old mice; predicts single-agent clinical activity unusually well. | Chesi et al., Cancer Cell 2008 |
| none | BCMA | none | Immunocompetent myeloma model with murine Bcma. | Chesi et al., Cancer Cell 2008 | |
| CVCL_2765, ACH-001239 | Melanoma, BRAF | BRAF | BRAF V600D metastatic line. | none | |
YUMM lines Braf V600E; Pten-/-; Cdkn2a-/- (and variants) Genetically defined syngeneic lines; YUMMER1.7 is a UV-irradiated immunogenic derivative. | none | Melanoma | none | Genetically defined syngeneic lines; YUMMER1.7 is a UV-irradiated immunogenic derivative. | Meeth et al., Pigment Cell Melanoma Res 2016 |
YUMM1.7 Mouse melanoma Mouse Braf V600E; Pten-/-; Cdkn2a-/- line derived from the GEMM, syngeneic in C57BL/6. | CVCL_JK16 | Melanoma | BRAF, PD-1 | Mouse Braf V600E; Pten-/-; Cdkn2a-/- line derived from the GEMM, syngeneic in C57BL/6. | none |
| CVCL_A2AX | PD-1 | PD-1, BRAF | UV-mutagenised Braf/Pten melanoma; responsive. | none | |
| CVCL_0588, ACH-000097 | HR-positive / HER2-negative breast cancer, Estrogen receptor | Estrogen receptor | ER-positive luminal line with wild-type PIK3CA. | none |
Before you pick a line
Check the Cellosaurus record for misidentification and contamination flags, confirm the allele you need in DepMap or Cellosaurus (G12C is not G12D), and authenticate your stock by STR profiling. Many historic lines are not what their names say.
Where to look next
- DepMap portal: Genome-wide CRISPR dependency and drug-sensitivity data on over 1,000 cell lines; the first place to check whether a target is essential in a lineage.
- PDCM Finder (cancermodels.org): EMBL-EBI and JAX meta-catalogue of PDX, organoid and cell-line models from dozens of providers.
- Human Cancer Models Initiative (HCMI): Next-generation organoid and conditionally reprogrammed models distributed through ATCC with matched sequencing.
- NCI Patient-Derived Models Repository (PDMR): Free-to-academics PDX, organoid and cell-line models with clinical annotation and sequencing.
Identifiers resolved from the Cellosaurus API on 2026-09-09; disease labels are Cellosaurus' NCIt terms. Repository links go to the portal, not to a specific model. Targets link to their dossiers.